Navigation Links
Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
Date:12/10/2007

Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast

Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced five posters to be presented at the 30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, from December 13 - 16, 2007. Following are details for each embargoed session:

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2007: Quantitative measurements of HER2 expression and

HER2:HER2 dimerization identify subgroups of HER2 positive metastatic

breast cancer patients with different probabilities of response to

trastuzumab treatment. (Presenter: W. Huang)

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2011: Development of novel proximity-based immunoassays for

the detection of HER heterodimerization in breast cancer cell line

lysates and formalin-fixed, paraffin-embedded tissue.

(Presenter: L. Eli)

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2012: Characterization of a novel proximity immunoassay for

the quantitative determination of HER2 protein expression and HER2

homodimerization in formalin-fixed, paraffin-embedded breast cancer

tissue. (Presenter: J. Winslow)

-- Saturday, December 15th, 2007, 7.00 am - 9.00 am CST

Abstract # 4108: Profiling HER-family receptor dimerization in HER2

over expressing cells that co-express mutated EGFR receptors.

(Presenter: R. Dua)

-- Saturday, December 15th, 2007, 5.00 pm - 7.00 pm CST

Abstract # 5002: Increased detection of breast cancer markers human

epidermal growth factor receptor dimer and downstream signaling

proteins utilizing the VeraTag technology with dextran modified

antibodies. (Presenter: J. Wallweber)

About HERmark(TM)

HERmark is a propriety diagnostic that accurately quantifies HER2 expression and dimerization in patients with breast cancer. Preliminary data from three cohorts of trastuzumab-treated patients with metastatic breast cancer who were identified as "HER2 positive" by conventional assays suggest that HERMark can identify patients who are likely to respond to Herceptin with greater precision than currently available tests, permitting stratification of patients according to their degree of clinical benefit from the drug. Additional studies of HERmark for breast cancer in both the metastatic and adjuvant settings are in progress.

About VeraTag(TM)

VeraTag is a proximity-based assay technology platform that accurately quantifies proteins and functional protein complexes. This platform provides a researcher or clinician a more thorough understanding of protein-protein interactions or signaling pathway activity allowing for disease characterization at the molecular level. VeraTag is designed to run on standard formalin-fixed paraffin embedded (FFPE) patient samples.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

VeraTag and HERmark are trademarks of Monogram Biosciences, Inc.

Contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held this past Thursday night at The Space in Hamden. ... their innovative project ideas to a panel of judges for an opportunity to ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... rallying cry to Americans to watch for the discomforts and hidden dangers of ... to senior citizens, everyone is at risk for developing fungal infections on the ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... unveiled the MirixaPro 6.0 platform. As the industry’s leading Medication Therapy Management ... delivered. Based on industry research and market feedback, the latest version of ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... high-quality orthopedic dog beds, has been officially recognized for its September 2016 donation ... , The company recently received three awards and honors for its contribution ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
Breaking Medicine News(10 mins):